In CLL, alterations in DNA methylation affect a large number of genes, including CD38 and SLC22 members [25,26], and hypomethylation programming is targeted to regions marked as enhancers and binding sites for various transcription factors, including NF-κB, AP-1 and Runx3 [26]. The gene discussed is CD38; the disease is B-cell chronic lymphocytic leukemia.